Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Personalis
PSNL
Personalis
Delays And Scrutiny Will Limit Revenue But Enable Future Adaptation
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
10 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$5.00
8.0% undervalued
intrinsic discount
16 Aug
US$4.60
Loading
1Y
-23.2%
7D
2.0%
Author's Valuation
US$5.0
8.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$5.0
8.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-110m
232m
2017
2019
2021
2023
2025
2027
2028
Revenue US$232.3m
Earnings US$29.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
26.21%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.34%
Calculation
US$29.75m
Earnings '28
x
40.50x
PE Ratio '28
=
US$1.20b
Market Cap '28
US$1.20b
Market Cap '28
/
194.82m
No. shares '28
=
US$6.18
Share Price '28
US$6.18
Share Price '28
Discounted to 2025 @ 7.34% p.a.
=
US$5.00
Fair Value '25
